Analytical_Development_Icon.png

 

Analytical Development 

PCT’s analytical development team works with clients to create testing methods that satisfy the Chemistry Manufacturing and Controls (CMC) requirements of an IND or BLA filing with the FDA. PCT develops analytical methods used for testing cell therapy products for identity, purity, potency and sterility, and also for certain additional measures of safety, as required by the FDA. PCT also performs assay validation services. 

 

 

Examples of analytical methods PCT can help clients develop include:

  • Identity -- cell surface phenotype associated with the therapeutic cell of interest (e.g., expression of the chimeric antigen receptor for CAR T cells, expression of CD4 and FoxP3 by regulatory T cells, expression of transgene in gene therapy approaches -- flow cytometry is typically used for such measurements).
  • Purity -- examples would include cell surface marker expression associated with unwanted/contaminating cells (typically by flow cytometry) 
  • Potency -- examples might include suppression of T cell proliferation by regulatory T cells, cytotoxicity assay for antigen-specific T cells, ability to form capillary-like structures for endothelial progenitor cells.  Also, for product release, surrogate markers associated with biologic activity may also be used (e.g., IL-12 secretion by dendritic cells).
  • Sterility -- compendial tests are typically used, but quick surrogate assays are sometimes developed for products that need to be infused fresh (an example would include Mycoplasma PCR)
  • Other measures of safety – for example, cellular proliferation assay to determine that tumor cell component used in some cancer therapies has been inactivated. 

Meet Our Experts

David_ONeill_Bio.png

David O’Neill, MD, Director, Analytical Development & Medical Director
MD Ohio State University

David is licensed to practice medicine in CA, NJ and NY, and is board-certified in anatomic pathology, clinical pathology and blood banking/transfusion medicine. He has over 20 years of academic and 5 years of industry research experience in hematology, immunology and stem cell biology, including the molecular biology and biochemistry of globin gene regulation, GMP production of cellular immunotherapies, vaccine design and immune monitoring for clinical immunotherapy trials for cancer, autoimmune disease and HIV infection.

In addition to analytical development, we also offer process development services. CLICK HERE to learn more.

Together, PCT’s process and analytical development services, combined with our Center for Innovation & Engineering, ensure that our cell therapy clients will have a manufacturing process that is optimized to deliver products in a reasonable timeframe, in a scalable, sustainable way that meets all applicable regulatory requirements.

Beginning the Journey with a Development by Design Mindset